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Background: To define the best strategy to reduce Compound
A production in Sevoflurane low-flow anaesthesia by experi-
ments in vitro and in vivo of different absorbers and different
anaesthesia machines.
Methods: In vitro Compound A has been measured at 45æC in
vitro following Sevoflurane interactions with potassium hydrox-
ide, sodium hydroxide, soda lime, Dragersorb 800 Plus and Am-
sorb, a new absorber that does not contain sodium or potassium
hydroxide. In vivo Compound A concentration in the anaes-
thesia circuit (inspiratory branch) has been measured using an
indirect sampling method through absorber vials (SKC) with ac-
tive coal granules, during low flows (500ml/min) general anaes-
thesia using soda lime, Dragersorb 800 Plus or Amsorb as ab-
sorber. Compound A was also measured during low flows (500
ml/min) general anaesthesia using as carbon dioxide absorber
soda lime with different anaesthesia machines.
SEVOFLURANE reacts with carbon dioxide absorbersproducing some vinyl compounds, of which the
most well known is Compound A (1). Compound A
has been demonstrated to be nephrotoxic in rats (2).
Compound A concentration increases with the in-
crease of the temperature of soda lime (3) and there-
fore in the low-flow anaesthesia due to the higher
temperatures of carbon dioxide absorbers. For this
reason the ‘Food and Drug Administration’ advises
not to use Sevoflurane with fresh gas flow less than 2
l/min.
Recently, new types of carbon dioxide absorbers to
reduce the production of Compound A during the an-
aesthesia techniques in closed circuit have been intro-
duced (4).
Moreover, some ventilation systems, like Physioflex
(Drager) (5–6) have aimed to reduce the Compound A
production by maintaining a very high gas circulation
inside the circuit, so to maintain the temperature of
the carbon dioxide absorber low.
The aim of the study has been to verify if during
low-flow anaesthesia (500ml/min) the production of
Compound A is affected by different types of carbon
1017
Results: In vitro at 45æC Compound A concentration with soda
lime and Dragersorb 800 Plus was about 10 times higher than
with Amsorb. In vivo the Compound A concentrations in the
inspiratory branch of the circuit were lower in the group with
Amsorb.
Conclusion:The Compound A production is minimal with Am-
sorb as carbon dioxide absorber.
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dioxide absorbers and/or by different anaesthesia
machines.
Therefore, the reaction ‘in vitro’ of various absorbers
with Sevoflurane and, in vivo, the amount of Com-
pound A production during Sevoflurane low-flow an-
aesthesia (500ml/min), with the various absorbers
and, with soda lime (ACEF), in different anaesthesia
machines has been analysed.
Methods
In vitro
Three carbon dioxide absorbers: soda lime (ACEF),
Amsorb (Amstrong) and Draegersorb 800 Plus (Drag-
er) were directly exposed to Sevoflurane at 45æC. (Am-
sorb contains about 83% of Ca(OH)2, 14.4% of H2O,
CaSO4 and CaCl2; soda lime contains about 80% of
Ca(OH)2, 3% of NaOH, 2% of KOH and 15% of H2O;
Draegersorb 800 Plus contains about 82% of Ca(OH)2,
2% of NaOH, 0.003% of KOH and 16% of H2O). More-
over, Compound A concentration was compared with
the ones obtained from Sevoflurane reactions with
potassium hydroxide (KOH, Carlo Erba) and sodium
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Fig.1. Inspiratory concentrations of Compound A during low-flow
(500ml/min) anaesthesia in Aestiva 3000. Group SL (nΩ5 patients):
CO2 absorber Ω soda lime; group Ds (nΩ5 patients): CO2 absorber Ω
Dragersorb 800plus (Drager); group Am (nΩ5 patients): CO2 absorb-
er Ω Amsorb (Armstrong). The difference between group Am and the
others is significant at all times.
hydroxide (NaOH, Carlo Erba) under the same con-
ditions.
Compound A concentration was determined ana-
lytically by a Varian gaschromatograph CP-3800
model provided with a flame ionization detector
(FID); Compound A retention time is 115s, while
Sevoflurane retention time is 180s.
In vivo
Compound A concentration during Sevoflurane low-
flow anaesthesia was assessed first using different ab-
sorbers in one machine (Aestiva 3000, Datex-Ohmeda)
and second using one absorber (soda lime, ACEF) in
two different anaesthesia systems.
Three homogeneous groups of patients scheduled
for major general surgery taking longer than 3h,
using an Aestiva 3000 machine, were exposed to
general low-flow (500ml/min) anaesthesia with
Sevoflurane: in five patients (group SL) soda lime
(ACEF) was used; while in another five patients
(group Am) Amsorb was used, and in the other
five (group Ds) Dragersorb 800 Plus was used. The
anaesthesia was maintained with Sevoflurane (1,5
MAC) with air 70% in oxygen. Compound A con-
centration was measured in the inspiratory branch
of the circuit by an indirect sampling through ab-
sorber vials (SKC) with active coal granules. Each
vial was connected on one side to the circuit and
on the other to a suction pump exactly regulated to
a 100-ml/min volumetric flow. Each sampling lasted
30min and analysis was performed immediately; the
samples were analysed with the Varian gas chrom-
atograph (CP-3800) obtaining the gas chromatograph
separation of Sevoflurane from its degradation com-
pounds.
In the second clinical test Compound A produc-
tion in vivo in low-flow circuit with two different
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anaesthesia systems and with soda lime as absorber
was evaluated. Ten patients were submitted to low-
flow (500ml/min) anaesthesia for general surgery
taking longer than 3h. In five patients (group S710)
Siemens 710 was used; in another five (group
A3000) Aestiva 3000 (Datex-Ohmeda) was used.
Sampling and measurements of Compound A was
performed as before; the temperature observed on
the surface of soda lime inside the canister was
registered.
The data are reported as mean∫standard deviation.
Comparisons between the different groups were done
with Student’s t-test A P-value lower than 0.05 was
regarded as statistically significant.
Results
In vitro test
Compound A concentrations with soda lime and Dra-
gersorb 800 Plus are about 10 times (at 3h) higher
than with the Amsorb.
In vivo tests
The three groups of patients were homogeneous re-
garding body surface (group SL: 1.8∫0.1m2; group
Am: 1.7∫0.3m2; group DS: 1.8∫0.2m2). In group SL
and Ds there was a Compound A concentration after
3h of anaesthesia of 7.9 and 7p.p.m., respectively, in
the inspiratory branch (Fig.1). Using Amsorb as a car-
bon dioxide absorber the concentration of Compound
A was less than 1 (p.p.m) (Fig.1).
The body surfaces of the two groups of patients of
the second clinical test were not different (Group
S710; 1.68∫0.18 m2, Group A3000; 1.66∫0.216m2). The
results are shown in Fig.2: Siemens 710 produces the
highest level of Compound A and the temperature ob-
Fig.2. Compound A production (p.p.m) during low-flow anaesthesia
(500ml/min) with three different anaesthesia systems. Group S710 Ω
Siemens 710; group A3000 Ω Aestiva 3000; *ΩP0.01 (Student’s
t-test), comparison between group S710 and Aestiva 3000 at each time.
Sevoflurane and Compound A
Fig.3. (a) Siemens 710; (b) simplified scheme of Aestiva (Datex-
Ohmeda). 1 Ω Inspiratory valve; 2 Ω expiratory valve; 3 Ω fresh gas
inlet port; 4 Ω breathing tube; 5ΩY- piece; 6 Ω reservoir bag; 7 Ω
PEEP valve; 8 Ω ventilator; 9 Ω overflow valve; 10ΩCO2 absorber;
11 Ω scavenging port; 12 Ω valve; 13 Ω unidirectional valve. Expli-
cations in the text. (modified from Zbinden et al. (16).
served in the canister was 31.9∫1.1æC and with Aesti-
va 3000, 28.8∫1.5C (PΩ0.007, Student’s t-test).
Discussion
Compound A is a potentially nephrotoxic product (7–
10).
The aim of the study was to define the best strategy
to minimize Compound A production.
Recently new carbon dioxide absorbers were pro-
duced and they appear to be able to reduce the pro-
duction of Compound A during low-flow general an-
aesthesia (4, 11).
The elimination of the bases sodium hydroxide and
potassium hydroxide from the usual carbon dioxide
absorbers decreases production of Compound A,
without materially decreasing the capacity of the re-
maining base, calcium hydroxide, to absorb carbon
dioxide (12, 13).
Our results confirm that Amsorb, in vitro test at high
temperature but also in the clinical one, obtains good
results to reduce the production of Compound A be-
cause of the absence of strong bases in its formulation.
This is confirmed by the literature about the new
products that have been put on the market in the re-
cent past (4, 14, 15).
Other clinical observations have shown that some
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ventilator systems like Physioflex (Drager) (5, 6) also
using closed circuit, produce a low concentration of
Compound A because, maintaining the circulation of
gases inside of the circuit at a high level, they contrib-
ute to maintain the temperature of the used carbon
dioxide absorber low.
The different position of the canister of carbon diox-
ide absorbers relative to the fresh gas inflow in the
circuit can modify the temperature of soda lime be-
cause the fresh gases are cold and dry. The ventilators’
circuits that are used in our experiment are schemat-
ized in Fig.3 (modified from Zbinden et al.) (16): in
the anaesthesia system Siemens 710 the position of the
canister of soda lime is far from the source of fresh
gases. This type of composition allows the tempera-
ture of the canister to reach the maximum levels in
relation to the carbon dioxide produced by the pa-
tient.
In the Aestiva anaesthesia systems, where (simpli-
fied in Fig.3b), the source of fresh gases is placed near
the CO2 absorber and the low temperature fresh gases
from the central gas system contribute to cool the con-
tent of the canister and to limit the production of
Compound A.
Conclusion
The production of Compound A is minimal if the
composition of soda lime does not provide strong
bases and is lower if the fresh gas enters the breathing
circuit closely upstream the absorber canister, which
cools the absorber mass more effectively than down
stream fresh gas delivery.
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